Menin-Inhibitor Targeted Maintenance in AML

Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.

NCT Number	NCT07563010
Lead Sponsor	Center for International Blood and Marrow Transplant Research Collaborators: National Marrow Donor Program, Dana-Farber Cancer Institute
Conditions	Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
Enrollment	146 participants
Start Date	2026-12
Primary Completion	2031-06 (estimated)
Study Completion	2031-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-22